hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in
preventing recurrent vascular events from ischemic heart disease patients, whose mechanism
consists in not only the reduction of serum lipid level but also anti-inflammatory effects.
Serum high sensitive CRP is known to be a predictor of cardiovascular events independent of
other conventional risk factors. The present substudy examine whether such pleiotrophic
effect of HMG-CoA reductase inhibitor (statin) which decreases high sensitive CRP would be
observed in the post-ischemic stroke patients who have already been registered in the
J-STARS, and the relationship the values of high sensitive CRP and recurrence of stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Translational Research Informatics Center, Kobe, Hyogo, Japan
Collaborators:
Hiroshima University Ministry of Health, Labour and Welfare, Japan Osaka University